What are the cancer concept stocks?

Let an expert guide you in stock trading, believe it or not! It doesn’t cost any money anyway, so you might as well give it a try! It will definitely open your eyes! No registration is required, no membership fee is required, you can try it for free first, and then cooperate!

Open this website and click on Get Bull Stocks for Free. You will get one of our recommended short-term bull stocks for free during the session: www.dncg777.com/

000790 Huashen Group 300006 Laimei Pharmaceutical 600267 Hisun Pharmaceutical 600276 Hengrui Pharmaceutical 600200 Jiangsu Wuzhong Anticancer Drug Cancer 600594 Yibai Pharmaceutical Vaccine Medicine 300158 Zhendong Pharmaceutical 300273 Hejia Share Electromagnetic

Anti-cancer concept stock speculation opportunities and anti-cancer stocks Summary of Cancer Concept Stocks★ Anti-cancer concept stocks are mainly hyped for new anti-cancer drugs. Cancer concept stocks are subdivided into cancer diagnosis and treatment institutions, cancer vaccines, cancer detection, and cancer auxiliary treatment.

Linkage concept: pharmaceutical sector

Active leaders: Laimei Pharmaceutical, Hisun Pharmaceutical, Hengrui Pharmaceutical, Jiangsu Wuzhong, Huashen Group, Yibai Pharmaceutical, Zhendong Pharmaceutical

Summary of listed companies related to anti-cancer concept stocks:

Cancer diagnosis and treatment institutions:

Hejia Shares (300273) cancer diagnosis and treatment institutions

In the field of minimally invasive tumor treatment: the company is the first and currently the only company in China that can provide relatively complete minimally invasive comprehensive tumor treatment solutions. We have successfully developed a series of professional equipment for minimally invasive tumor treatment. The equipment covers the main core areas of minimally invasive tumor treatment such as internal radiotherapy, radiofrequency ablation, interventional thermochemotherapy, extracorporeal hyperthermia, immune recovery therapy, and treatment of late-stage pleural and ascites effusion. The interventional thermochemotherapy perfusion system and immunotherapy system are both original inventions and have been included in the first list of recommended equipment by the State Administration of Traditional Chinese Medicine. The subsequent development of electromagnetic positioning puncture navigation systems, dual-frequency electromagnetic hyperthermia machines and other products will enable the company to achieve self-produced equipment covering the main technical fields of minimally invasive tumor treatment. At present, the company's minimally invasive tumor treatment equipment covers 155 tertiary hospitals (coverage rate reaches 12.57) and 172 second-level hospitals (coverage rate reaches 2.64).

Huashen Group (000790) Cancer Diagnosis and Treatment Institutions/Anti-Cancer Drugs

The company’s primary liver cancer drug iodine [131I] metuximab injection (licartin ) is a national first-class innovative drug and the world's first genetic drug that uses monoclonal antibodies to target liver cancer. The company has independent intellectual property rights for the treatment of intermediate and advanced liver cancer. Cooperated to build three cancer diagnosis and treatment centers.

Duyiwei (002219) Cancer Diagnosis and Treatment Institution

The company invested 120 million yuan to acquire 85% of the income rights of the Red Cross Cancer Diagnosis and Treatment Center for 15 years. According to the asset appraisal, the operating income rights of the Red Cross Cancer Diagnosis and Treatment Center in 15 years 85 are valued at 142 million yuan. From January to November 2012, the diagnosis and treatment center achieved a net income of 31.441 million yuan. In addition, the company and the Red Cross Cancer Hospital plan to entrust the medical management and business development of the cancer diagnosis and treatment center to Yaoyu Company.

Cancer detection related:

Cache Testing (300012) carcinogen detection technology

Nitrosamines are strong carcinogens and can cause cancer through the placenta and breast milk Tumors in future generations, as well as teratogenic and mutagenic effects, the company has successfully developed detection of 11 nitrosamine substances of major concern; phosphate flame retardants have potential carcinogenicity, teratogenicity, neurotoxicity and other toxicities, the company has developed a gas phase Chromatography-mass spectrometry technology is used to detect these five substances; organochlorine pesticides can cause large-scale and long-term harm to humans and animals, causing human endocrine disorders, damaging reproductive and immune systems, and inducing cancer and Neurological diseases, for this reason, the company has developed detection methods for 34 organochlorine pesticides specified by AAFA. The above three technologies have reached the international advanced level.

Xilong Chemical (002584) Cancer Detection Reagents

Plans to acquire 75% stake in New World Biotech, which has a registered capital of 20 million yuan and has developed tumor detection reagents, total antioxidant status ( TAS) detection kits (FRAP method), multiple types of biochemical reagents, etc., have a certain market size in the in vitro diagnostic reagent industry; if the acquisition is completed, the company will enter the biochemical reagent industry, providing new growth points for future development.

Tigermed (300347) Clinical Medical Experiment

The company mainly provides phase I to IV clinical trial technical services, data management, statistical analysis, registration application and other clinical research for pharmaceutical product research and development. Serve. As a clinical trial CRO (contract research organization) company, the company has a high level of clinical research and is one of the few local CRO companies capable of conducting international multi-center trials. It has also been in a leading position in the clinical research field of innovative drugs. It has clinical research experience in 35 Class I new drugs, covering many fields such as hepatitis, tumors, endocrinology, cardiovascular and cerebrovascular diseases, and AIDS.

Rongzhilian (002642) Cancer Genome Sequence

BGI joins hands with South Texas START Company to launch San Antonio Thousand Cancer Genome Project, September 12, 2013, Global Shenzhen BGI Technology Services Co., Ltd. ("BGI"), a subsidiary of BGI, the largest genetics research institution, and South Texas Accelerated Research Therapeutics (South Texas Accelerated Research Therapeutics) officially announced that the two parties will jointly carry out and promote the San Antonio 1000 Cancer Genome Project (SA1kCGP). This project's pioneering combination of genetic variation and clinical characterization will further promote the development of personalized medicine with drug-specific markers. The SA1kCGP project is entirely funded by private donations, and all genome-wide data on 10 common cancers obtained during the study will be made freely available to researchers around the world. The semi-annual report of Rongzhilian (002642) shows that it used 15 million yuan of its own funds to invest in Shenzhen Huada Gene Technology Services Co., Ltd.

Fosun Pharma (600196) Cancer Chemotherapy Drug Testing

The company invested US$22.4 million to subscribe for 4.2994 million Series D preferred shares of SALADAX. After this subscription is completed, the company will become its sole largest shareholder. At the same time, SALADAX authorized the company's subsidiary Fosun Long March to have exclusive distribution rights and product manufacturing rights in China. SALADAX has the world's leading detection technology and tumor chemotherapy drug monitoring product portfolio. Through this cooperation, the company will effectively enhance the company's innovation capabilities in the field of medical diagnosis, and is expected to launch a unique biochemical detection platform in China and even the global market. It can detect the concentration of tumor chemotherapy drugs, etc., which can help better analyze the therapeutic effect of tumor chemotherapy drugs. It is expected that this product line will form a considerable sales scale in the country in the future.

Daheng Technology (600288) Cancer Detection Equipment

Among the company's medical equipment, it has the world-class "three-dimensional stereotactic conformal and intensity-modulated radiotherapy system (3DCRT, IMRT) for whole-body tumors" ”, and the leading-generation “Three-dimensional Radiotherapy Planning System (3DTPS) and Digital Virtual Human Body Technology (VHP)” are large-scale comprehensive medical devices that integrate computer technology, image processing technology, and radiotherapy equipment. Due to its undisputed technical advantages, the product has been installed in more than 200 famous hospitals across the country, ranking first in the domestic market share.

Cancer vaccine related:

Haixin Co., Ltd. (600851) intestinal cancer vaccine/anti-cancer drug

Independently developed a national first-class new drug, the drug is called " "Antigen-sensitized human dendritic cells (APDC)" can be used to treat rectal cancer. It was jointly developed by Haixin Biotechnology Company (the company holds 51 shares) and Shanghai Second Military Medical University. It is a national first-class new drug and the first in my country. The independently developed APDC therapeutic vaccine for advanced colorectal cancer was officially approved by the State Food and Drug Administration (SFDA). The "antigen-sensitized human dendritic cells" (APDC) developed by Haixin Biotechnology is a new generation of therapeutic tumor vaccine developed for colorectal cancer. (On July 26, 2012, the APDC project received approval from the State Food and Drug Administration to conduct Phase III clinical trials.)

Watson Biotech (300142) Cervical Cancer Vaccine

Holding Shanghai Zerun (shareholding ratio 50.69). Shanghai Zerun is a domestic leader in the research and development of preventive and therapeutic cervical cancer vaccines (HPV). The recombinant HPV preventive vaccine it developed is the first HPV vaccine in China that uses a eukaryotic expression system to develop and obtain clinical trial approval. .

Zhifei Biological (300122) Cervical Cancer Vaccine

The company signed an agreement with Merck & Co., an affiliate of Merck, on the "Cervical Cancer Vaccine" (HPV vaccine) and agreed on the products of the agreement After listing, the company is licensed to distribute exclusively within the agreement area (Mainland China). Merck's HPV vaccine (trade name: Jiadaxu) is the world's first cancer vaccine and the only cancer vaccine approved to be marketed to prevent cervical cancer and reproductive organ precancerous lesions caused by HPV types 6, 11, 16 and 18. , currently on the market in 124 countries and regions around the world.

Cancer drugs:

Guonong Technology (000004) anti-cancer drugs

The holding subsidiary Huatai Pharmaceutical plans to invest a total of 213.48 million yuan to expand production in Penglai. base. The project scale is to produce 22 million ordinary small-volume injections, 22 million ordinary freeze-dried powder injections, and 10 million anti-tumor freeze-dried powder injections annually. The construction period is planned to be 2.5 years, and the production period is 1.5 years. In the long run, some of the products in the project are currently imported from China. The current market is relatively good and sales are relatively stable.

The research and development period of Sinopharm Accord (000028)

The anti-tumor drug Doradazole developed by the company's joint venture Wanle Pharmaceutical (accounting for 35.19%).

Fengyuan Pharmaceutical (000153) anti-cancer drug

Fengyuan Zhongren Pharmaceutical (the company holds 60 shares), a joint venture between the company and Zhongren Technology, guarantees the anti-cancer drug of cisplatin implants. New cancer drugs will be launched before the end of September 2012; the company invests heavily in the research and development of new drugs for adjuvant cancer treatment.

Sihuan Biological (000518) anti-cancer drugs

The company’s main products include a new class of anti-cancer drugs, recombinant human interleukin-2 for injection (used for kidney cancer, malignant melanoma and other Comprehensive treatment of malignant tumors), recombinant human interleukin-2 injection, recombinant human granulocyte stimulating factor injection, and recombinant human erythropoietin injection, of which recombinant human interleukin-2 for injection is a national project "Genetically Engineered Human Interleukin-2" 2's development, pilot production and clinical application of "industrialized genetic engineering products"; Beijing Sihuan Biopharmaceutical, which still holds 55% of the shares, is the earliest enterprise in my country engaged in the research and production of genetically engineered drugs and diagnostic reagents. Its proprietary technologies include interleukin 2 (for liver cancer treatment), interferon, EPO, G-CSF and other sublingual tablets.

Hainan Haiyao (000566) anti-cancer drug

Bendamustine, a subsidiary of Haikou Pharmaceutical Factory, is an anti-tumor drug with dual action mechanisms of nitrogen mustard and purine analogues , there is no bendamustine currently on the market or imported in China, and it is a new chemical drug in Category 3.1. The paclitaxel injection produced by the company is the first product to be marketed in China. Paclitaxel is mainly used for first-line and second-line treatment of ovarian cancer, breast cancer and NSCLC. It is also used for head and neck cancer, esophageal cancer, seminoma, recurrent non-Hodgkin's lymphoma, etc. It also has certain curative effects and has brand and price advantages.

Changchun High-tech (000661) anti-cancer drugs

The company’s holding subsidiary Changchun Jinsai Pharmaceutical (Holding 70) is the only national-level genetic engineering pharmaceutical incubation base among pharmaceutical companies in the country. Its growth hormone series products have ranked first in the country and even in Asia-Pacific, becoming a leader in the field of children's growth and development treatment. It is also establishing a leading position with core competitive advantages in many fields such as burns and scalds, assisted reproduction, anti-aging, and tumors. . Jinsai Pharmaceutical continues to maintain the first place in the auxin market share in the country.

Puluo Co., Ltd. (000739) anti-cancer drug

The company holds 98.07 of Beishixin produced by Zhejiang Puluo Kangyu Pharmaceutical, which is a national second-class anti-tumor new drug; the company went public in 2010 The "High-tech Industrialization Demonstration Project for Genetically Engineering Enzymatic Synthesis of D-p-Hydroxyphenylglycine Deng Potassium Salt" applied for half a year was included in the national high-tech industrialization demonstration project. The Pharmaceutical Industrial Park (Second Park) of Datong Development Zone in Shanxi Province carries out the development and construction of pharmaceutical and R&D bases. After the project is completed, the estimated production capacity is 100 million pieces/year of water injections and 20 million pieces/year of freeze-dried powder injections. The total investment of the project is 250 million yuan, which is divided into two phases. The company has currently completed the application for four products of cardiovascular and cerebrovascular injections, and they are waiting for review at the Drug Evaluation Center. At the same time, preliminary research work on 4 featured tumor injection products has been completed.

Peking University Pharmaceuticals (000788) R&D period

Compridin disodium phosphate (CA4P) and its injection, which the company cooperates with Founder Pharmaceutical Research Institute, are a vascular targeting drug or endothelial The mechanism of drug destruction is to cause rapid interruption of the blood supply to the tumor, causing the tumor to die due to insufficient oxygen supply and nutritional starvation. The production approval of this drug takes about 5-6 years. Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist. It is mainly used to treat and prevent acute nausea and vomiting caused by moderately and severely emetogenic chemotherapy. It is mostly used as an auxiliary drug for tumors and postoperative nausea and vomiting in clinical practice. Prevention and treatment. After the drug is launched, it will have a positive impact on the company's future performance improvement.

China Resources Sanjiu (000999) anti-cancer drug

Anhui Jinchan Biochemical, in which the company holds 83.68 shares, mainly produces anti-cancer drug Cinochansu Injection, which can be used for intermediate and advanced tumors. Chronic hepatitis B and other diseases must be treated.

Huabang Yingtai (002004) anti-cancer drug

The company's holding subsidiaries Chongqing Huabang and Chongqing Huabang Shengkai received the approval and issuance of the "Levoleucovorin" drug by the State Food and Drug Administration Drug registration approval documents for "Calcium API" and "Levoleucovorin Calcium for Injection" (Chemical Drug Category 3.1). Levavavorin calcium for injection is Chongqing Huabang's second drug in the oncology field and has a positive impact on further improving the product line in the oncology field. Clinically, injectable leucovorin calcium combined with fluorouracil is used for adjuvant treatment of gastric cancer and colorectal cancer, which can prolong survival. As the corresponding isomer of calcium leucovorin for injection, levoleucovorin calcium for injection has obvious advantages in product efficacy and safety.

Shuanglu Pharmaceutical (002038) anti-cancer drug

The company was selected into the "Beijing Biomedical Industry Leap-forward Development Project" and the first batch of "Ten, Hundred, Thousand Projects" in the Zhongguancun National Independent Innovation Demonstration Zone Focus on cultivating enterprises. The company has stocked up on a number of superior varieties with domestic and foreign market potential in the fields of tumor treatment, anti-inflammatory analgesia, cardiovascular and cerebrovascular and liver diseases, and strives to launch more than three antibody and vaccine drugs. In the field of liver disease treatment, we continue to cultivate blockbuster varieties and strive to become an important enterprise in the field of liver disease treatment in China. The company's main products, including recombinant human granulocyte colony-stimulating factor, interleukin-11, asparaginase, and anti-tumor products, are gradually entering the Eastern European, Asian, and South American markets.

Xinlitai (002294) clinical trial period

Jointly established the "Tsinghua University-Xinlitai Small Molecule Joint Research and Development Center" with Tsinghua University to improve cardiovascular and cerebrovascular, anti-tumor, etc. Ability to screen innovative drugs in the field of major diseases to improve research and development efficiency; introduce the preparation production technology involved in the national Class 1 innovative drug - allisartan medoxomil, and obtain the production approval for clopidogrel bisulfate tablets 75MG and 300MG and the clinical approval for lercanidipine tablets .

Zhongsheng Pharmaceutical (002317) anti-cancer drug

Signed a three-party technical cooperation agreement with the Guangdong South China New Drug Creation Center and Sichuan University to jointly develop new drug projects. The three projects developed in the first phase are: QU100, a new chemical class I drug for pulmonary fibrosis, WCH-016, a new chemical class I drug for type 2 diabetes, and DXZ923 nano-preparation project for cancer.

R&D period of Jingjing Pharmaceutical (002349)

Developing the second-generation targeted anti-tumor drug betatinib: The drug has opened up the synthesis route, completed the salt and crystal form screening, and prepared A small number of samples are currently undergoing preliminary quality and stability inspection of the raw materials.

Yuheng Pharmaceutical (002437) anti-cancer drug

Gemcitabine hydrochloride - anti-tumor drug: Gemcitabine hydrochloride for injection is an antimetabolite tumor drug and is widely used in the treatment of pancreatic cancer and Non-small cell lung cancer is produced by only three pharmaceutical companies in my country: Eli Lilly, Jiangsu Hansoh Pharmaceuticals and Yuheng Pharmaceutical.

Laimei Pharmaceutical (300006) anti-cancer drugs

The company’s core technologies include nanomedicine technology for lymphatic targeted therapy, drug micro-nano dispersion and suspension preparation technology and sterile raw materials Drug preparation technology, among which, nanomedicine technology for lymphatic targeted therapy is at the international leading level; anti-tumor drugs are mainly nanocarbon suspension injection, fludarabine phosphate for injection, and parenteral nutrition drugs are mainly N(2)- L-Alanyl-L-Glutamine Injection has filled a domestic gap and has great clinical application value. The proportion of the company's oncology drugs in its product mix will continue to increase. The company's current ratio of anti-tumor drugs is around 20%, and it is expected to surpass anti-infective drugs and reach around 40% within three years. The company's product, nanocarbon suspension injection, is mainly used for lymphatic tracing. Its advent as a diagnostic lymphatic tracer has filled the domestic gap. It is the first generic drug of this type in my country. The related product preparation technology has obtained national patent protection. The company is the first in the world to launch this product. Fludarabine phosphate for injection is suitable for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL). According to statistics, in the domestic fludarabine phosphate for injection market, the company occupies a market share of 10.35%, ranking third in the market.

Anke Bio (300009) anti-cancer drug

The company plans to introduce the anti-tumor drug Tigeol tablet project. Tigeol is a new compound anti-tumor drug, mainly used for For the treatment of advanced or metastatic gastric cancer, it is expected to be put into production in 2012, with an annual production capacity of 30 million tablets.

R&D period of Xiangxue Pharmaceutical (300147)

The new drug company has paid a total of US$1.5 million to KINEX Company as agreed. It is expected that it will take more than 5-6 years to develop KX02 into a new drug. In June 2013, KINEX received IND approval from the U.S. FDA. After submitting and revising relevant documents, it can start the Phase I clinical research of the compound (KX2-361) in the United States. At the same time, KINEX will also launch the first phase of clinical research of the KX02 project as planned. KX02 is a lipophilic anti-tumor compound that can pass through the blood-brain barrier and has a clear mechanism of action. It has been proven by animal experiments to effectively inhibit malignant glioma cells and may be developed into an effective new drug for the treatment of brain tumors.

Clinical Trial Period of Renfu Pharmaceutical (600079)

Hubei Gedian Renfu Pharmaceutical, which the company holds 81.07 shares of, is a company specializing in steroid hormone APIs and fertility regulation drugs. and anti-tumor drug R&D and production enterprises; Shenzhen Xinpeng Bioengineering, in which the company holds a 52% stake, is developing TR-1, an internationally leading anti-cancer gene drug project, and is expected to obtain a Class I new drug certificate within 3-5 years.

Taiji Group (600129) anti-cancer drugs

Joined with scientific research institutes to develop 4 new drugs with independent intellectual property rights: new anti-cancer drug preparations, new diabetes (complications) drugs and There are 2 new cardiovascular drugs, 2 of which have obtained clinical approval, and 1 is in the process of applying for production approval. We have independently screened 901, 902, 903, 904, and 905 new product projects.

The process research of DXJS, the first new anti-tumor drug formulation at home and abroad, has been completed, and the preclinical research has entered a comprehensive summary stage. It is expected to complete clinical application in 2013.

Jiangsu Wuzhong (600200) clinical trial period

Wuzhong Medicine, a holding subsidiary, is currently researching the "National Class I biological anti-cancer new drug recombinant human endostatin injection" The "R&D and Industrialization" project is in the stage of applying for Phase III clinical research and has independent intellectual property rights. In 2006, it was supported by the national "863" project for non-small cell lung cancer.

Tailong Pharmaceutical (600222) R&D Period

The company has decided to use anti-tumor and cardiovascular and cerebrovascular products as new research and development directions in the next stage of development. Product dosage forms Mainly small volume injections and freeze-dried powder injections.

Zhongheng Group (600252) R&D period

The company agrees to provide Peking University with no more than 100 million yuan in cooperative scientific research funding within ten years, 10 million yuan in the first year, and annual thereafter The research progress and funding budget support its research on early diagnosis of cancer by single-cell sequencing. Project-related research should be combined with the therapeutic mechanism and direction of the company's related products (such as didehydrated durabolol, etc.) to facilitate the promotion of the product.

Hisun Pharmaceutical (600267) Anticancer Drugs

The company is China’s leading API manufacturer and one of the largest antibiotic and anti-tumor drug production bases in China; The preparation export base project has an annual output of 25 million bottles of cytotoxic anti-tumor liquid injections, 25 million bottles of freeze-dried powder injections, and 160 million solid preparations; the company's genetic drug tumor necrosis factor receptor antibody fusion protein has now entered Phase II clinical trials stage.

Hengrui Medicine (600276) anti-cancer drug

The company’s single-enantiomer chiral drug, levoleucovorin calcium, can be used to enhance the anti-tumor activity of 5-fluorouracil and is mainly used to treat Symptoms related to folate antagonism and colon cancer and kidney cancer after osteosarcoma treatment with high-dose methotrexate; the company's multiple anti-tumor drugs rank first in the country, three of which are exclusively produced in China, and the existing generic drugs Austria Salibar and docetaxel are in the growth stage, and irinotecan is also entering the rapid growth stage; the company wants to have the molecularly targeted anti-tumor drug apatinib mesylate.

Merro Pharmaceuticals (600297) anti-cancer drug

Anti-tumor drug amifostine: The anti-tumor drug amifantine is the company’s flagship product, and the standard name of the drug is for injection Amifostine belongs to the category of Western medicine injections. It can selectively protect normal organs from the toxic attacks of chemotherapy and radiotherapy, and is suitable for treating patients with malignant hematological diseases during radiotherapy and chemotherapy for various tumor patients. The "Research on Improving the Quality and Technical Standards of Amifostine and Preparations" undertaken by the company was included in the national 12th Five-Year Plan major new drug creation projects.

Yabao Pharmaceutical (600351) Anti-cancer drugs

Anti-tumor drugs for injection, such as vindesine sulfate and other freeze-dried powder injection preparations.

Clinical trial period of Conba (600572)

The "recombinant high-efficiency compound interferon" developed by the Far East Super Laboratory in which the company's wholly-owned subsidiary Hong Kong Conba Company has a stake has obtained the approval of Singapore Approved for Phase I clinical trials, this drug is a new non-natural interferon with a new spatial conformation successfully developed using protein spatial regulation technology. It can be used to inhibit viral replication and anti-tumor treatment. Far East Laboratory was registered and established in the British Virgin Islands on October 28, 2005. It is mainly engaged in the research and development of cancer treatment drugs based on recombinant high-efficiency compound interferon (RSIFN-CO) products and technologies.

Yibai Pharmaceutical (600594) anti-cancer drug

The company has the anti-tumor traditional Chinese medicine Aidi injection product with genetic technology. In addition, the purchased products can use genetic engineering methods to obtain polypeptide chain products. VEGI's proprietary technology can directly activate different types of immune cells to inhibit or eliminate cancer cells. The research on Aidi injection has reached the genetic level (Aidi injection is an anti-tumor traditional Chinese medicine and is the company’s exclusive product). The company’s first-line product Aidi is an exclusive variety of anti-tumor traditional Chinese medicine injection, accounting for about 45% of its revenue.

Aidi's sales in tertiary hospitals account for about 80% of the sales of this variety. Lobaplatin is the latest third-generation platinum anti-tumor drug on the market. It is the only exclusive variety among the five platinum-based anti-tumor drugs in China. It is currently in rapid development. growth period.

Qiji Pharmaceutical (600613) anti-cancer drug

The company's subsidiary Guizhou Jinqiao Pharmaceutical small-volume injection (anti-tumor drug) has passed the national new version of GMP certification and passed the publicity period yesterday. It is reported that the anti-cancer drug that passed GMP certification this time is Sodium Cantharidin Injection. The company holds 92.58% of the equity of Jinqiao Pharmaceutical. Sodium cantharidin injection is suitable for the treatment of tumors such as primary liver cancer. The 2013 interim report showed that sodium cantharidin injection and related products constituted nearly 20% of the company's main operating income.

Harbin Pharmaceutical Co., Ltd. (600664)

The bioengineering company is mainly committed to the production and sales of drugs for tumors, cardiovascular and cerebrovascular diseases, and liver diseases. Products currently on the market include recombinant human interferon ɑ-2B for injection (trade name: Lifeneng), recombinant human erythropoietin injection (trade name: Xuedasheng), and recombinant human granulocyte stimulating factor injection (trade name : Riadin) and other bioengineering pharmaceutical products, as well as new chemical preparations such as alprostadil fat emulsion, among which the market shares of recombinant human interferon ɑ-2B for injection and alprostadil injection are in the leading position in the country.

Listed companies with non-pharmaceutical main businesses related to anti-cancer concepts:

Zhongzhu Holdings (600568) R&D period

The holding subsidiary Qianjiang Pharmaceutical and the United States TNI The company is cooperating in preclinical research on blood and bone marrow hematopoietic system cancers and anti-cancer drugs to restore immunity in cancer patients. Qianjiang Pharmaceutical’s pre-clinical trial expenses are expected to be RMB 10 million. If clinical approval is not obtained, the paid clinical trial will be refunded. 80 for the front fee.

Jianfeng Group (600668) Anti-cancer Drugs

Jianfeng Pharmaceutical, a holding subsidiary, will form a raw material production line with an annual output of 35 tons of cephalosporins, anti-tumor drugs and other raw materials after the completion of the project ( Supporting preparations) and 200 million various powder injection production lines. Announced on April 10, 2012, Jianfeng Pharmaceutical, in which the company controls 99.16%, plans to invest 39 million yuan (paid in installments based on stage results) to cooperate with China Pharmaceutical University and its Institute of Pharmaceutical and Chemical Engineering and other relevant parties to develop a new class of anti-tumor drugs ( DPT) preclinical studies.

Eastern Sunshine Aluminum (600673) research and development period

Eastern Sunshine Aluminum’s joint-stock company develops new anti-hepatitis B and tumor drugs, and the scientific research of East Sunshine innovative drugs introduced by Guangdong Dongguangguang Pharmaceutical Co., Ltd. The team takes anti-tumor and anti-viral chemical Class 1.1 new drugs as its main research and development direction, and is committed to developing Class 1.1 new chemical drugs with internationally advanced levels. At present, there is no such drug on the market in the world. If the project is successfully developed, it will fill the gap in the field of new tumor drugs in China.

Lansheng Co., Ltd. (600826) anti-cancer drug

The company invested 34.65 shares in Lansheng Guojian Pharmaceutical and CITIC Pacific *** to jointly invest in the establishment of "Shanghai CITIC Guojian Pharmaceutical Co., Ltd. ", Lansheng Guojian accounted for 41.69, and the company accounted for 0.73. In 2008, the new biological drug "Yisapu" (recombinant human tumor necrosis factor receptor type 11-antibody fusion protein for injection) developed by CITIC Guojian won the National Science and Technology Invention Award The second prize is the first humanized monoclonal antibody drug that has been truly industrialized and marketed in my country. The construction of four 750-liter cell culture production lines has been completed and successfully put into operation, with an annual production capacity of 4 million mg-level charges.

Yatai Group (600881) Anti-cancer Drugs

The company takes biological vaccines and anti-tumor series of drugs as the development direction of new products, and has formed "Shenyi Capsules", anti-cancer biological missiles As the leading anti-cancer product series, it also reserves new anti-cancer drugs under development such as interleukin-11 and ginsenoside RG3 injection.

Cancer auxiliary treatment:

Zhendong Pharmaceutical (300158) Cancer auxiliary treatment

The core leading product Yanshu injection is an auxiliary treatment drug for cancer and has the ability to inhibit cancer. It has the functions of reducing sexual pain and bleeding, inhibiting tumor growth, and increasing efficacy and reducing toxicity in combination with radiotherapy and chemotherapy.

Yiling Pharmaceutical (002603) Traditional Chinese Medicine for Anti-cancer/Assistant Treatment of Cancer

Yiling Research Institute, a wholly-owned subsidiary of the company, has established a pharmaceutical research center in cooperation with Cardiff University in the UK. The center will carry out in-depth exchanges and cooperation around the anti-tumor target research and clinical application of traditional Chinese medicine, as well as the sharing of market resources. Research has found that Yangzheng Xiaoji Capsule can inhibit tumor angiogenesis, thereby inhibiting tumor growth and metastasis. Yangzheng Xiaoji Capsules are mainly used for auxiliary treatment of tumors, and combined with chemotherapy drugs can help improve the efficacy of chemotherapy. Yangzheng Xiaoji Capsules combined with interventional treatment of primary liver cancer have significant efficacy in increasing efficiency and reducing toxicity, enhancing immunity, improving syndromes, and improving quality of life.

Haisike (002653) Cancer Adjuvant Treatment

The company's subsidiary Liaoning Hesike's national Class 6 chemical drugs "methylprednisolone succinate" and "methylprednisolone sodium succinate for injection" "Obtained drug registration approval. Methylprednisolone is currently one of the most widely used adrenocortical hormone drugs and can be used clinically in the treatment of critically ill patients in many departments, such as allergic diseases, malignant tumors, etc. Methylprednisolone (injection) is a Class B drug in the National Medical Insurance List. After the drug is launched, it will enrich the company's product line and have a positive impact on the company's future performance improvement.

Jinhua Co., Ltd. (600080) Cancer Assisted Treatment

Transfer factor oral solution is used to treat viral infections and autoimmune diseases. It can also be used as an adjuvant treatment for malignant tumors and tumor patients after radiotherapy and chemotherapy.

Pien Tze Huang (600436) Chinese medicine anti-cancer/cancer auxiliary drug

The main ingredients of Pien Tze Huang include bezoar, musk, notoginseng, and snake gall. In addition to treating acute and chronic viral hepatitis caused by heat, poison and blood stasis, carbuncles and boils, unknown swelling, bruises and various inflammations, it can also inhibit the growth of cancer cells in the digestive system and can be used as an anti-tumor auxiliary drug. The company applied The patent for research and development was obtained and accepted.

Kangyuan Pharmaceutical (600557) Traditional Chinese Medicine Anti-cancer/Cancer Auxiliary Drugs

The Tong'an Injection produced by it is a pure traditional Chinese medicine injection used to treat moderate and severe cancer pain. With independent intellectual property rights, the company plans to use effective promotion to at least partially replace opioid analgesics within a few years and become the first-line variety of domestic cancer pain treatment drugs.

Anti-tumor drug intermediates:

Fu'an Pharmaceutical (300194) anti-tumor drug intermediate-aztreonam API

Jincheng Pharmaceutical (300233) anti-tumor drug intermediate Oncology drug intermediates - phenyl isocyanate

Yaben Chemical (300261) Anti-tumor drug intermediates-small molecule targeted anti-tumor drugs and their intermediates stock theory